A Phase IV, Multicenter, Single-Arm, Open-Label Study of Emicizumab Prophylaxis in Patients With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures
Phase of Trial: Phase IV
Latest Information Update: 28 Nov 2018
At a glance
- Drugs Emicizumab (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Genentech
- 03 May 2018 Planned initiation date changed to 31 May 2018.
- 07 Feb 2018 Status changed from not yet recruiting to recruiting.
- 08 Jan 2018 Planned initiation date changed from 29 Dec 2017 to 17 Jan 2018.